Aldevron, LLC entered into an agreement to acquire global exclusive license for Codex® HiCap RNA Polymerase from Codexis, Inc. (NasdaqGS:CDXS) on December 13, 2023. Under the terms of the deal, Aldevron will receive global manufacturing and commercialization rights to the Codex® HiCap RNA Polymerase and Codexis will receive payments for near-term technical milestones, along with commercial milestones and sales-based royalties.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.05 USD | +14.66% | +6.64% | 0.00% |
Apr. 11 | Codexis, Inc. Appoints Carole Cobb to Its Strategic Advisory Board | CI |
Feb. 29 | Benchmark Upgrades Codexis to Buy From Hold, Price Target is $9 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 215M | |
+1.77% | 42.86B | |
+47.70% | 41.36B | |
+12.24% | 42.74B | |
-8.83% | 27.68B | |
+7.44% | 25.15B | |
-23.01% | 18.63B | |
+30.56% | 12.37B | |
-1.82% | 11.92B | |
+8.35% | 11.21B |
- Stock Market
- Equities
- CDXS Stock
- News Codexis, Inc.
- Aldevron, LLC entered into an agreement to acquire global exclusive license for Codex® HiCap RNA Polymerase from Codexis, Inc..